Cargando…

Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial

ABSTRACT: The investigational NEDD8‐activating enzyme inhibitor pevonedistat is being evaluated in combination with azacitidine versus single‐agent azacitidine in patients with higher‐risk myelodysplastic syndrome (higher‐risk MDS), higher‐risk chronic myelomonocytic leukemia (higher‐risk CMML), or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Xiaofei, Friedlander, Sharon, Kupperman, Erik, Sedarati, Farhad, Kuroda, Shingo, Hua, Zhaowei, Yuan, Ying, Yamamoto, Yuka, Faller, Douglas V., Haikawa, Kazue, Nakai, Katsuhiko, Bowen, Sharon, Dai, Yi, Venkatakrishnan, Karthik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212745/ https://www.ncbi.nlm.nih.gov/pubmed/33503305 http://dx.doi.org/10.1111/cts.12972

Ejemplares similares

Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies
por: Faessel, Hélène M., et al.
Publicado: (2019)

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours
por: Faessel, Hélène, et al.
Publicado: (2019)

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
por: Zhou, Xiaofei, et al.
Publicado: (2022)

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [(14)C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
por: Zhou, Xiaofei, et al.
Publicado: (2020)

The necessary conduct: Exploratory multiregional clinical trials in East Asia
por: Jeon, Inseung, et al.
Publicado: (2021)

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
por: Lockhart, A Craig, et al.
Publicado: (2018)

Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine
por: Handa, Hiroshi, et al.
Publicado: (2022)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

ABCG2 Overexpression Contributes to Pevonedistat Resistance
por: Kathawala, Rishil J., et al.
Publicado: (2020)

Integration of patient-reported outcomes in multiregional confirmatory clinical trials()
por: Gnanasakthy, Ari, et al.
Publicado: (2013)

Molecular pathology quality control in Southeast Asia: Results of a multiregional quality assurance study from MASTER KEY Asia
por: Okuma, Hitomi Sumiyoshi, et al.
Publicado: (2023)

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes
por: Swords, R T, et al.
Publicado: (2017)

Multiregional Tumor Trees Are Not Phylogenies
por: Alves, João M., et al.
Publicado: (2017)

The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma
por: Foster, Jennifer H., et al.
Publicado: (2021)

Multiregional origins of the domesticated tetraploid wheats
por: Oliveira, Hugo R., et al.
Publicado: (2020)

Multiregion neuronal activity: the forest and the trees
por: Machado, Timothy A., et al.
Publicado: (2022)

Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway
por: Xu, Junfeng, et al.
Publicado: (2022)

The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis
por: Wolenski, F S, et al.
Publicado: (2015)

Multiregional genetic evolution of metastatic uveal melanoma
por: Rodriguez, Daniel A., et al.
Publicado: (2021)

Asia‐Inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status Quo
por: Venkatakrishnan, Karthik, et al.
Publicado: (2022)

International oncology drug approvals for multiregional or single-country clinical trials: A systematic review
por: Zhang, Min, et al.
Publicado: (2022)

Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer
por: Ferris, Jennifer, et al.
Publicado: (2020)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
por: Snow, Anson, et al.
Publicado: (2022)

Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer
por: Thomsen, Mathilde Borg Houlberg, et al.
Publicado: (2017)

A Multiregional Proteomic Survey of the Postnatal Human Brain
por: Carlyle, B. C., et al.
Publicado: (2017)

Tracing the evolution of aneuploid cancers by multiregional sequencing with CRUST
por: Chattopadhyay, Subhayan, et al.
Publicado: (2021)

Multiregional neural pathway: from movement planning to initiation
por: Mao, Xing-feng, et al.
Publicado: (2022)

Overall Survival Prediction of Glioma Patients With Multiregional Radiomics
por: Shaheen, Asma, et al.
Publicado: (2022)

A Rare Case of Multiregional Spinal Stenosis: Clinical Description, Surgical Complication, and Management Concept Review
por: Hong, Choon Chiet, et al.
Publicado: (2014)

Sample size determination for a specific region in multiregional clinical trials with multiple co-primary endpoints
por: Huang, Wong-Shian, et al.
Publicado: (2017)

Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2022)

Subclonal diversification of primary breast cancer revealed by multiregion sequencing
por: Yates, Lucy R, et al.
Publicado: (2015)

Intratumor heterogeneity of lymphoma identified by multiregion sequencing of autopsy samples
por: Makishima, Kenichi, et al.
Publicado: (2021)

A Global Multiregional Proteomic Map of the Human Cerebral Cortex
por: Guo, Zhengguang, et al.
Publicado: (2022)

Ultrasound-based multiregional radiomics analysis to differentiate breast masses
por: Chen, Ziman, et al.
Publicado: (2023)

Points to Consider for Implementation of the ICH E17 Guideline: Learning from Past Multiregional Clinical Trials in Japan
por: Asano, Kunihito, et al.
Publicado: (2020)

Multiregional integration in the brain during resting-state fMRI activity
por: Hay, Etay, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8bpjvctlp4btga6vgg4filmh98